Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
CymaBay Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT01336686
First received: April 14, 2011
Last updated: August 24, 2012
Last verified: August 2012
  Purpose

The purpose of the study is to evaluate the safety and effectiveness of MBX-102 compared to placebo when given orally once daily for 4 weeks for the treatment of hyperuricemia in patients with gout.


Condition Intervention Phase
Hyperuricemia
Gout
Drug: Arhalofenate
Drug: Placebo comparator
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of MBX-102 in the Treatment of Hyperuricemia in Patients With Gout

Resource links provided by NLM:


Further study details as provided by CymaBay Therapeutics, Inc.:

Primary Outcome Measures:
  • Serum uric acid [ Time Frame: Baseline and end of treatment phase (4 wks) ] [ Designated as safety issue: No ]

Enrollment: 67
Study Start Date: May 2011
Study Completion Date: November 2011
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arhalofenate 400 mg Drug: Arhalofenate
Arhalofenate 400 mg once daily for 4 weeks
Other Name: MBX-102
Experimental: Arhalofenate 600 mg Drug: Arhalofenate
Arhalofenate 600 mg once daily for 4 weeks
Other Name: MBX-102
Placebo Comparator: Placebo Drug: Placebo comparator
Matching placebo once daily for 4 weeks

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Read and sign the informed consent after the elements of consent have been fully explained and all questions have been addressed, prior to any study procedures.
  • Known gout patient (per criteria of the American Rheumatism Association for the classification of the acute arthritis of primary gout in Appendix 3)

    • the sUA must be ≥ 8.0 mg/dL and ≤12 mg/dL
    • if on ULT, the patients must agree to temporarily discontinue their existing ULT and the sUA must be ≥ 8.0 mg/dL and ≤12 mg/dL after wash-out at Week -1
  • Male or female, 18-75 years of age at Screening Visit
  • All female patients must be surgically sterile or post-menopausal (at least 45 years of age with no history of menses for at least 2 years; or any age with no history of menses for at least 6 months and serum FSH ≥ 40 mIU/mL) or have a partner who has undergone vasectomy or must agree to use two medically accepted methods of contraception including a barrier method (see the list in Appendix 4) for the entire duration of the study unless reporting complete sexual abstinence.
  • Female patients must not be pregnant or lactating
  • Male patients with a female partner of child-bearing potential must agree to use condom or the partner must use a medically acceptable method of contraception for the entire duration of the study.
  • Patients must have an estimated CrCl ≥ 60 mL/min as calculated by the Cockcroft-Gault method
  • Serum creatinine value must be ≤ 1.1 mg/dL in females and ≤ 1.3 mg/dL in males
  • Patients must have liver function tests ≤ 1.5X ULN for AST, ALT and T-bilirubin, ≤ 2X ULN for ALP, ≤ 3X ULN for GGT; and ≤ 3X ULN for CK
  • All other clinical laboratory parameters must be within normal limits or considered not clinically significant for participation in this study
  • Electrocardiogram (ECG) must be normal, or if abnormal, considered not clinically significant for participation in this study
  • Patients must have a systolic blood pressure ≤ 160 mm Hg and a diastolic blood pressure ≤ 90 mm Hg; known hypertensive patients controlled with medication other than thiazide diuretics (BP reading as above) may be included

Exclusion Criteria:

  • Known or suspected secondary hyperuricemia (e.g. due to myeloproliferative disorder, or organ transplant).
  • Known patient with xanthinuria
  • History of documented or suspected kidney stones
  • Over producers of uric acid as evidenced by 24-hour urinary uric acid > 800 mg (on normal unrestricted diet)
  • Known infection with the human immunodeficiency virus (HIV) or history of viral hepatitis type B or C
  • History of illicit drug or alcohol abuse within last 1 year
  • History of significant pulmonary disease, upper GI bleeding, documented peptic ulcer disease (unless known H. pylori infection treated successfully without recurrence), or nephrotic syndrome within last 3 years
  • All patients must not have had a stroke, TIA, acute myocardial infarction, congestive heart failure (NYHA Class II-IV), angina pectoris, coronary intervention procedure (including but not limited to angioplasty, stent placement, coronary revascularization), lower extremity bypass procedure, systemic or intracoronary fibrinolytic therapy within last 5 years
  • Malignancy within the last 5 years (except resected basal cell carcinoma)
  • Body mass index (BMI) > 42 kg/m2
  • Current or expected requirement for anticoagulant therapy (except for ≤ 325 mg/day aspirin and/or Plavix® 75 mg/day)
  • Rheumatoid arthritis or other autoimmune disease requiring ongoing treatment
  • Current or expected treatment with potent CYP3A4 inhibitors (See in Appendix 6), ranolazine, digoxin, cyclosporine, cyclophosphamide and other cytotoxic agents, sulphonylurea, thiazolidinedione, diuretic, atypical antipsychotic agents, and phenytoin
  • Chronic treatment with non-steroidal anti-inflammatory drugs (NSAIDs use to treat acute flares are permitted)
  • Current or expected treatment with systemic corticosteroids (except topical, ophthalmic, intra-articular, or inhaled at a dose < 1600 μg/day) other than to treat acute flares
  • Known hypersensitivity to colchicine
  • Treatment with any other investigational therapy within the 30 days prior to the Screening Visit, or patients who received at least one dose of blinded study drug while enrolled in any previous MBX-102 trial
  • Any other condition that compromises the ability of the patient to provide informed consent or to comply with the objectives and procedures of this protocol, as judged by the investigator and/or medical monitor
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01336686

Locations
United States, Arizona
Tucson, Arizona, United States
United States, California
Los Angeles, California, United States
United States, Florida
Boca Raton, Florida, United States
Jupiter, Florida, United States
Tampa, Florida, United States
United States, Hawaii
Honolulu, Hawaii, United States
United States, Maryland
Wheaton, Maryland, United States
United States, Missouri
St. Louis, Missouri, United States
United States, New York
New York, New York, United States
United States, North Carolina
Raleigh, North Carolina, United States
United States, Ohio
Cincinnati, Ohio, United States
United States, Utah
West Jordan, Utah, United States
Sponsors and Collaborators
CymaBay Therapeutics, Inc.
  More Information

No publications provided

Responsible Party: CymaBay Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT01336686     History of Changes
Other Study ID Numbers: M102-21122
Study First Received: April 14, 2011
Last Updated: August 24, 2012
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Gout
Hyperuricemia
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Purine-Pyrimidine Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on July 26, 2014